Further patients benefit from drug against Long COVID
Covid Lists
Long COVID: Study Says Synbiotic Drug That Alters Gut Microbiome Relieves Multiple Symptoms
NIH Launches Trials for Long COVID Treatment Breakthroughs
Intravenous immunoglobulin as a potential treatment for long COVID
Large Review Suggests IVIG is Effective for Neurological Diseases Following COVID-19 Infection
Efficacy of intravenous immunoglobulin (IVIg) on COVID-19-related neurological disorders over the last 2 years: an up-to-date narrative review - PubMed
Long-term high-dose immunoglobulin successfully treats Long COVID patients with pulmonary, neurologic, and cardiologic symptoms
Clinical and CSF single-cell profiling of post-COVID-19 cognitive impairment
Interferon-λ treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity
Long COVID Looks Like Acute Infection in the Brain
Frontiers | Corrigendum: Case Series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequalae of COVID (PASC)
Study Details | Antiviral Clinical Trial for Long Covid-19 | ClinicalTrials.gov
RECOVER Clinical Trials | Home
How monoclonal antibodies lost the fight with new COVID variants
Study Shows How Paxlovid Resistance Emerges in Persistent Infections
“This type of approach helped to improve HIV drugs, and we think it’s a good way to improve antivirals against SARS-CoV-2,” says Sho Iketani, PhD, assistant professor of medical sciences at Columbia University’s Vagelos College of Physicians and Surgeons and Aaron Diamond AIDS Research Center, who co-led the research with David D. Ho, MD, the Clyde '56 and Helen Wu Professor of Medicine, professor of microbiology & immunology, and director of the Aaron Diamond AIDS Research Center, and Haitao Yang, PhD, of ShanghaiTech University.
Monoclonal antibody levels and protection from COVID-19
Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir
Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B
Broad-spectrum antiviral activity of two structurally analogous CYP3A inhibitors against pathogenic human coronaviruses in vitro
Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout | Clinical Infectious Diseases | Oxford Academic
Real-Time Whole Genome Sequencing to Guide Patient-Tailored Therapy of Severe Acute Respiratory Syndrome Coronavirus 2 Infection | Clinical Infectious Diseases | Oxford Academic
Luteolin: A promising natural agent in management of pain in chronic conditions
Luteolin
Pharmacological Activity of Eriodictyol: The Major Natural Polyphenolic Flavanone
Eriodictyol - an overview | ScienceDirect Topics
TREAT ME Survey: Individual Treatment Results
Lumbrokinase, a Fibrinolytic Enzyme, Prevents Intra-Abdominal Adhesion by Inhibiting the Migrative and Adhesive Activities of Fibroblast via Attenuation of the AP-1/ICAM-1 Signaling Pathway
Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome | Clinical Infectious Diseases | Oxford Academic
Fibrin drives thromboinflammation and neuropathology in COVID-19
Degradative Effect of Nattokinase on Spike Protein of SARS-CoV-2
Informing Blacks with Long Covid